PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.31%
Negative R&D growth (spending reduction) needs careful analysis. Benjamin Graham would examine impact on competitive position.
-49.44%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
3.87%
Other expenses growth 0-10% reflects moderate increase. Benjamin Graham would investigate nature of expenses.
-37.34%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-37.34%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
-62.14%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
3.87%
D&A growth 0-5% reflects moderate asset expansion. Benjamin Graham would check if growth drives future value.
47.24%
EBITDA growth above 15% demonstrates exceptional operating performance. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
37.34%
Operating income growth above 15% demonstrates exceptional core profitability. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
1271.24%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
47.13%
Pre-tax income growth above 15% demonstrates exceptional profitability improvement. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
-62.14%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
47.13%
Net income growth above 15% demonstrates exceptional bottom-line expansion. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
50.90%
EPS growth above 15% demonstrates exceptional shareholder value creation. Warren Buffett would verify sustainability.
52.86%
Diluted EPS growth above 15% demonstrates exceptional value creation despite potential dilution. Warren Buffett would verify sustainability.
7.67%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
12.32%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.